Final Program

116 SUNDAY • MAY 15
Chairing: M.J.C. Humbert, MD, PhD, Le Kremlin Bicetre, France
I. Lang, MD, Vienna, Austria
N. Voelkel, MD, Richmond, VA
2:15 A Patient’s Perspective
J. Mato, Chowchilla, CA
2:20 Fifty Years of Anorexigen-Induced PAH: From Aminorex to
Benfluorex
M.J.C. Humbert, MD, PhD, Le Kremlin Bicetre, France
2:40 Drug Induced Pulmonary Veno-Occlusive Disease
D. Montani, MD, PhD, Le Kremlin Bicetre, France
3:00 Pulmonary Hypertension as a Complication of Chronic
Amphetamine Abuse
R.T. Zamanian, MD, Stanford, CA
3:20 Impact of Aberrant Drug Metabolism in Drug Induced PH:
Lessons Learned from CES1
V. De Jesus Perez, MD, Stanford, CA
3:35 From Mechanism to Disease: A Perspective on Drug Induced PH
N. Voelkel, MD, Richmond, VA
3:55 Pharmacovigilence and Drug Safety in the Current Therapeutic
Environment
M.R. Southworth, PharmD, Silver Spring, MD
A90
There will be a 5-minute discussion after each talk.
BASIC • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
ABNORMAL METABOLISM: EMERGING CONCEPTS
IN UNDERSTANDING LUNG DISEASE
Assemblies on Respiratory Cell and Molecular Biology; Allergy,
Immunology and Inflammation; Clinical Problems; Pulmonary
Circulation; Thoracic Oncology
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 2016/2018 (West Building, Level 2)
Target Audience
Basic and clinician scientists, clinicians, public health officials, student and
postdoctoral trainees with an interest in the biology of metabolism and its role
in respiratory disease.
Objectives
At the conclusion of this session, the participant will be able to:
• improve the health of patients by identifying new biomarkers for disease using
metabolomics approaches;
• identify metabolic modifiers in lung disease;
• understand how metabolic processes can contribute to lung disease.
This session will provide information about the impact of metabolic processes in the
development and progression of lung diseases. Topics will include many pulmonary
diseases, including fibrosis, hypertension, cancer, and COPD, but will all include the
underlying theme of the role of altered metabolism. The goal of this session is to fill a
knowledge gap in our understanding of the role that metabolic pathways and
metabolites play in lung disease.
Chairing: P.J. Sime, MD, Rochester, NY
S. Archer, MD, Kingston, Canada
J.L. Judge, MS, Rochester, NY
G. Liu, MD, PhD, Birmingham, AL
2:15 Metabolic Reprogramming and Hypoxia in Pulmonary Arterial
Hypertension
K.R. Stenmark, MD, Aurora, CO
2:35 The Role of Metabolic Dysregulation in the Development of
Pulmonary Fibrosis
R.M. Kottmann, MD, Rochester, NY
2:55 Metabolic Proteins as Drug Targets for Lung Cancer
I. Stratford, PhD, Manchester, United Kingdom
3:15 Metabolic Reprogramming in Aging and Lung Fibrosis
V.J. Thannickal, MD, Birmingham, AL
3:35 Beyond ATP: Mitochondria as Signaling Organelles
N. Chandel, PhD, Chicago, IL
3:55 Using Metabolomics Approaches to Identify Biomarkers in
Development of Lung Diseases
C.H. Wendt, MD, Minneapolis, MN
A91
BEHAVIORAL • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
HOT TOPICS IN DISPARITIES IN PULMONARY,
CRITICAL CARE AND SLEEP MEDICINE
Assemblies on Allergy, Immunology and Inflammation; Behavioral Science
and Health Services Research; Clinical Problems; Critical Care;
Environmental, Occupational and Population Health; Microbiology,
Tuberculosis and Pulmonary Infections; Nursing; Pediatrics; Pulmonary
Circulation; Pulmonary Rehabilitation; Respiratory Cell and Molecular
Biology; Respiratory Structure and Function; Sleep and Respiratory
Neurobiology; Thoracic Oncology
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 2001/2003 (West Building, Level 2)
Target Audience
Clinicians, researchers and public health practitioners in the fields of pediatric
and adult pulmonary, critical care and sleep medicine.
Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about the impact of major barriers to the care of minority
patients with pulmonary, critical care and sleep disorders;
• apply new strategies to care for minority patients, and advocate for health
equality;
• discuss feasible and necessary policies to achieve respiratory health equality.
Health disparities are commonly encountered in pediatric and adult pulmonary,
critical care and sleep medicine. Attainment of respiratory health equality requires
the ending of respiratory health disparities, which can be achieved only through
multidisciplinary efforts. In this symposium, we will first review and discuss
state-of-the-art approaches to overcoming major barriers to health equality, namely
non-adherence, lack of access to personalized medicine, healthcare for migrant
populations, and inadequate communication with minorities who are critically ill.
ATS 2016 • San Francisco